Friday, July 21, 2017 7:36:55 PM
You were seeing the picture,Gator.
but I don't remember seeing any of your charts.
Please feel free to post what you like at my study forum.
You haven't posted that much at AVXL, but I can see that you have some good vision.
I managed to place a stink bid last night at 4.10, which was about the lowest target (4.00) I could see in the technical chart for this cycle. It was some Giant plunge that took it to 3.63 today.
Folks here don't like to see too many complex charts in this forum, but do feel free to analyze it with me at my forum.(or Here, till we get yelled at...)
Right now, as the dust and smoke needs time to clear and we watch what the 'recovery/repair' process looks like, I'm starting to see the new (reset) pattern target points on the chart, for the bounce, for resistance, for support , etc.... I agree we have to be onguard for another retrace to try and finish the 'bottoming process' The first peak and pivot and bounce coming off the 3.63 bottom, hit the 4.10 area and then held at 3.85 twice,as the first support step. There was also a pivot before that at 3.77
The current 4.00-4.10 area looks like the basic support zone to watch now. and overhead there is resistance at 4.30 area,the first rally peak, and above that 4.50-4.80 is the resistance danger zone for this first bounce to get attacked again. unless it starts lower, around 4.40
Remember back before the big rally to 6.64 started, there was a Resistance zone sliding sideways along the 4.20-4.30 area,4.40-4.30, and that's also where the 200ma was at the time. It needed to break above the 4.28 line I remember, and then as it did, we got the surge to peak at 6.64.
Now the same reset game starts all over again by the looks of this.
AVXL had not much of a day today for giggles and hugs
but I don't remember seeing any of your charts.
Please feel free to post what you like at my study forum.
You haven't posted that much at AVXL, but I can see that you have some good vision.
I managed to place a stink bid last night at 4.10, which was about the lowest target (4.00) I could see in the technical chart for this cycle. It was some Giant plunge that took it to 3.63 today.
Folks here don't like to see too many complex charts in this forum, but do feel free to analyze it with me at my forum.(or Here, till we get yelled at...)
Right now, as the dust and smoke needs time to clear and we watch what the 'recovery/repair' process looks like, I'm starting to see the new (reset) pattern target points on the chart, for the bounce, for resistance, for support , etc.... I agree we have to be onguard for another retrace to try and finish the 'bottoming process' The first peak and pivot and bounce coming off the 3.63 bottom, hit the 4.10 area and then held at 3.85 twice,as the first support step. There was also a pivot before that at 3.77
The current 4.00-4.10 area looks like the basic support zone to watch now. and overhead there is resistance at 4.30 area,the first rally peak, and above that 4.50-4.80 is the resistance danger zone for this first bounce to get attacked again. unless it starts lower, around 4.40
Remember back before the big rally to 6.64 started, there was a Resistance zone sliding sideways along the 4.20-4.30 area,4.40-4.30, and that's also where the 200ma was at the time. It needed to break above the 4.28 line I remember, and then as it did, we got the surge to peak at 6.64.
Now the same reset game starts all over again by the looks of this.
AVXL had not much of a day today for giggles and hugs
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
